Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Zoetis Inc (ZTS) Adds Pershing Square’s William Doyle To Board

Page 1 of 2

Zoetis Inc (NYSE:ZTS) has entered into an agreement with Bill Ackman’s Pershing Square to appoint William Doyle to the company’s board of directors, a new filing with the U.S. Securities and Exchange Commission showed.

Mr. Doyle is a member of Pershing Square’s Investment Team, and his appointment will expand the size of company’s board to ten from nine directors. According to the filing, Pershing Square is the largest shareholder of Zoetis Inc (NYSE:ZTS), in which the fund holds 41.82 million shares, representing 8.3% of common stock shares outstanding.

Bill Ackman in crowd

Pershing Square is a New York-based hedge fund founded and run by Bill Ackman. Mr. Ackman is a long term value investor, who takes advantage of short term downward moves in prices. He is particularly successful at special situations investments. Pershing Square had around $12 billion in assets under management in early 2014. The fund lost 1.1% in 2011 but gained 12.4% in 2012, 9.7% in 2013. Pershing Square has a very concentrated portfolio. As of the end of September 2014, the value of the fund’s equity portfolio totaled $13.4 billion. Allergan Inc. (NYSE:AGN), Canadian Pacific Railway Limited (USA) (NYSE:CP), and Air Products & Chemicals Inc. (NYSE:APD) were represented as the largest shareholders of Zoetis Inc (NYSE:ZTS) as of the end of September 2014.

Bill Ackman is the notorious investor. Last month, in an interview on Bloomberg Television, Mr. Ackman has discussed his investment strategy, as well as provided its opinion regarding oil prices decline and mentioned that he was considering investing in the UK retailer Tesco PLC (LON:TSCO), among other things. During his interview with Bloomberg TV’s Francine Lacqua and Guy Johnson, Mr. Ackman stated that the main target of Pershing Square’s investment strategy are high quality companies that run a predictable business model and are capable of generating free cash flow. Moreover, Pershig Square also prefers to invest in companies that are not exposed to commodity prices and have unique assets and long-term contracts, among other factors.

Mr. Ackman tried to acquire Allergan, Inc. (NYSE:AGN) jointly with Valeant Pharmaceuticals Intl Inc (NYSE:VRX). However, even though, after a pretty rough proxy fight, Allergan was sold to Actavis plc (NYSE:ACT) instead of Valeant. In November, Mr. Ackman’s Pershing Square disclosed taking a massive position in Zoetis Inc (NYSE:ZTS). At that time, we made an assumption that Pershing Square might pursue Zoetis Inc (NYSE:ZTS) into selling itself to Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!